SpaceX and OpenAI plan to reserve part of their shares on the stock exchange for individuals, and SpaceX may have a record high. The National Fund of Uzbekistan, which owns stakes in Uzbekistan Airways and Uzbekhydroenergo, will hold a dual listing in London and Tashkent. Supermarket chain 7-Eleven postponed its US offering due to weak financials. The main events on the IPO market for the week - in our selection.

SpaceX, OpenAI and the London listing of Uzbekistan's national fund: highlights of the IPO by April 12

Hims & Hers Health, Inc.

Novo Nordisk A/S

Eli Lilly and Company

LifeMD, Inc.

“The enemy of my enemy is my friend,” points out Ilya Zubkov, Freedom Broker senior equity analyst, describing the situation that has unfolded this year between Danish pharmaceutical giant Novo Nordisk and telehealth platform and online pharmacy operator Hims &amp; Hers Health. The “enemies” are Novo Nordisk and its U.S. rival Eli Lilly, which have been competing for leadership in the obesity drug market for several years. Their rivalry has spilled over beyond the pharmaceutical sector, now affecting companies like Hims &amp; Hers Health. Overall, the weight-loss drug market is beginning to shift. Which small caps should investors watch?

The obesity therapy market is changing. What smid-cap investors should know.

HSBC analysts called the market for obesity drugs "bloated"

Eli Lilly received a rare "sell" recommendation from analysts. Shares fell by 6%

U.S. site Hims &amp; Hers could announce a renewed partnership with Denmark's Novo Nordisk as soon as Monday

Shares of online pharmacy Hims &amp; Hers soared 40% amid a general sell-off. What is it?

JPMorgan, Deutsche Bank and RBC Capital believe that pharmaceutical company Eli Lilly will be the main beneficiary of the rapidly growing market of GLP-1 weight loss drugs. Analysts point to the higher efficacy of its therapy compared to competitors, development of direct sales and potential expansion of insurance coverage.

Three investment banks named Eli Lilly as the leader in the weight loss drug race

NVIDIA Corporation

Advanced Micro Devices, Inc.

PayPal Holdings, Inc.

First Solar, Inc.

The Home Depot, Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: Nvidia will set the bidding vector

Danish company Novo Nordisk <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916504">has announced</a> its intention to reduce list prices in the US for its flagship weight loss and diabetes drugs Wegovy and Ozempic. Their prices will be reduced by up to 50% starting next year, according to the company. Novo said it expects to increase the affordability of the therapy in this way, especially for those who pay for the treatment themselves - partially or fully.

Novo Nordisk to cut prices on weight loss products by up to 50%. Why is the stock falling?

A key objective of the trial was to confirm that Novo was as effective as a competitor's product, Eli Lilly

Novo's failure to test a weight loss drug has sparked a sell-off in the Danish market

U.S. telehealth platform and online pharmacy Hims &amp; Hers Health will <a href="https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Agreement-to-Acquire-Eucalyptus-Accelerating-Its-Vision-to-Become-the-Leading-Global-Consumer-Health-Platform/default.aspx">acquire</a>&nbsp;Australian peer Eucalyptus. The deal comes as the company <a href="https://finance.yahoo.com/news/hims-hers-1-2-billion-165104901.html">seeks</a>&nbsp;to reshape investor perceptions after U.S. regulators <a href="https://en.oninvest.com/article/novo-shares-rise-cheap-copy-of-its-drug-fails-to-survive-criticism-from-us-regulatorhttps://en.oninvest.com/article/novo-shares-rise-cheap-copy-of-its-drug-fails-to-survive-criticism-from-us-regulatorhttps://en.oninvest.com/article/novo-shares-rise-cheap-copy-of-its-drug-fails-to-survive-criticism-from-us-regulator">criticized</a>&nbsp;it over the sale of a copycat of Novo Nordisk’s obesity drug Wegovy and the Danish drugmaker filed a lawsuit.

Hims & Hers to buy Australian peer Eucalyptus amid GLP-1 regulatory, legal pressure

Viking Therapeutics, Inc.

Risk-tolerant investors should not ignore shares of biotech Viking Therapeutics, Motley Fool analyst Adria Cimino <a href="https://www.fool.com/investing/2026/02/11/viking-therapeutics-the-undertheradar-glp1-contend/">argues</a>. This is because the company is developing an obesity drug that could compete with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound in the near term.

Motley Fool calls Viking the GLP‑1 drugmaker growth-hunting investors 'can't ignore'

Ichor Holdings, Ltd.

ON Semiconductor Corporation

Upwork Inc.

Credo Technology Group Holding Ltd

Medpace Holdings, Inc.

The Goodyear Tire & Rubber Company

Microsoft Corporation

Alphabet Inc.

Valaris Limited

STMicroelectronics N.V.

Workday, Inc.

Micron Technology, Inc.

monday.com Ltd.

Morning in New York: Statistics and Fed rhetoric will set the tone for trading

At issue is an unlicensed in the U.S. tablet version of the weight-loss drug Wegovy, which competitor Novo hoped to sell for several times cheaper than the original product